Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/20846
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMurphy, Declan G-
dc.contributor.authorHofman, Michael S-
dc.contributor.authorAzad, Arun-
dc.contributor.authorViolet, John-
dc.contributor.authorHicks, Rodney J-
dc.contributor.authorLawrentschuk, Nathan-
dc.date2019-05-24-
dc.date.accessioned2019-06-05T01:28:39Z-
dc.date.available2019-06-05T01:28:39Z-
dc.date.issued2019-05-24-
dc.identifier.citationBJU International 2019; online first: 24 May-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/20846-
dc.description.abstractThe value of a multidisciplinary approach to the management of prostate cancer (PC) is widely appreciated by both health care professionals and patients alike. Whether for the navigation of localised PC where management options can be perplexing, or the management of advanced prostate cancer where therapy options are evolving rapidly, and clinical trial options abound, it is best practice that patients are offered multidisciplinary options[1]. This may include the presence of health care practitioners of various types in a physical multidisciplinary clinic, or having a virtual network whereby patients can access multidisciplinary care in different environments. Importantly, a well-run multidisciplinary team (MDT) meeting is the key to anchoring such care and considering all multidisciplinary options for prostate cancer patients. Indeed, this approach is mandated by law in the UK where multidisciplinary care was enshrined in the Health Care Act based on the Improving Outcome Guidance work which underpins cancer care in the National Health Service in the UK. This article is protected by copyright. All rights reserved.-
dc.language.isoeng-
dc.subject#PCSM-
dc.subject177Lu-PSMA-617-
dc.subjectLutetium-
dc.subjectNeoplasm metastasis-
dc.subjectPSMA protein-
dc.subjectProstate neoplasm-
dc.subjectRadioimmunotherapy-
dc.subjectTheranostic Nanomedicine-
dc.subjectligands-
dc.titleGoing nuclear - It is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team.-
dc.typeJournal Article-
dc.identifier.journaltitleBJU International-
dc.identifier.affiliationDepartment of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australiaen
dc.identifier.affiliationDivision of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen
dc.identifier.affiliationSir Peter MacCallum, Department of Oncology, The University of Melbourne, Victoria, Australiaen
dc.identifier.affiliationMolecular Imaging and Nuclear Medicine Therapeutics, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDivision of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen
dc.identifier.doi10.1111/bju.14814-
dc.identifier.orcid0000-0001-8553-5618-
dc.identifier.pubmedid31127664-
dc.type.austinLetter-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

12
checked on Feb 3, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.